KARPAS 384 Human T-cell non-Hodgkin’s Lymphoma cell line useful in oncology research, developed at the University of Cambridge.

Publications:

Dyer et al. (1993). Leukemia, 7, 1047–1053

Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. We have partnered with ECACC (The European Collection of Cell Cultures; a Public Health England Culture Collection) to manage distribution of the majority of these cells on our behalf. Enquires to either organisation are welcomed.